A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.
Put together by software, not yet checked by a person
Why this status
8 Jun 2015: Trial registered, NCT02465060
17 Aug 2015: Trial started, NCT02465060
The trials
NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
State
Under way
Phase
Phase 2
People
6,452 planned
Started
17 Aug 2015
Primary completion
31 Dec 2027
Arms
Subprotocol Q (HER2 amplification)
Results
None posted
8 Jun 2015: Trial registered
17 Aug 2015: Trial started
How the status changed
19 Nov 2026: First set: Phase 2 trial
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.